Abivax minor Ph. III read-out delay
Yesterday after close, Abivax provided an update on the enrollment status into its ABTECT phase III study, disclosing a single quarter delay in the expected read-out, now scheduled for Q2 2025. Considering the complexity of the study (600 sites, 1,200 patients) we do not see any red flags in such m
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.